Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerns: low revenue, increased commercial expenses, and a significant net loss. Despite positive elements like reduced R&D and G&A expenses, and an Express Scripts agreement, the Q&A highlights uncertainties, especially regarding prescription volume and payer coverage. The lack of clear guidance on free drug distribution and payer expansion further clouds the outlook. Overall, the financial strain and ambiguous responses suggest a negative sentiment, likely impacting the stock price negatively in the short term.
Key Financial Performance
Cash, Cash Equivalents, and Short-Term Investments $184 million as of March 31, 2026, compared to $106 million at December 31, 2025. The increase is primarily due to a $75 million cash payment received in January from a royalty purchase agreement with RTW and approximately $19 million from ATM sales and Series A warrant exercises during Q1.
Operating Cash Burn $23.7 million during Q1 2026.
Product Revenues $0.2 million in Q1 2026.
R&D Expense $3.3 million in Q1 2026 compared to $5 million in Q1 2025, a decrease primarily due to reduced outside service costs related to drug development and research.
G&A Expense $4.8 million in Q1 2026 compared to $5.2 million in Q1 2025, a decrease primarily due to lower professional costs, partially offset by increased personnel costs.
Commercial Expense $15.8 million in Q1 2026 compared to $10.4 million in Q1 2025, an increase primarily due to additional personnel costs, professional costs, and other operational costs related to the launch of CARDAMYST.
Net Loss $26.1 million or $0.20 per share in Q1 2026 compared to $20.8 million or $0.31 per share in Q1 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Launch of CARDAMYST: CARDAMYST, a rapid-acting self-administered prescription therapy for acute PSVT episodes, was launched within two months of FDA approval. It has received positive feedback from healthcare providers and patients, with 600 prescriptions written by over 400 unique healthcare professionals for 560 unique patients by the end of April 2026.
Phase III trial for AFib-RVR: Initiated the Phase III trial for atrial fibrillation with rapid ventricular rate (AFib-RVR), named ReVeRa-301. The trial builds on successful Phase II results and uses the same dose and operational approach as the approved CARDAMYST for PSVT.
Insurance Coverage Expansion: Express Scripts, a major pharmacy benefit manager, added CARDAMYST to its commercial national formularies, covering approximately 25% of commercially insured lives in the U.S. Negotiations with other PBMs and health plans are ongoing.
Financial Position: The company has $184 million in cash and investments as of March 31, 2026, providing runway into the second half of 2027. Operating cash burn for Q1 2026 was $23.7 million.
Revenue and Expenses: Product revenues for Q1 2026 were $0.2 million. R&D expenses decreased to $3.3 million, while commercial expenses increased to $15.8 million due to the CARDAMYST launch.
Focus on disciplined execution: The company is prioritizing disciplined commercial launch execution, expanding payer access, advancing clinical development programs, and managing resources responsibly to sustain momentum in 2026 and beyond.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Commercial Launch of CARDAMYST: The aggressive timeline for the launch of CARDAMYST, while successfully met, could pose operational risks such as supply chain disruptions, logistical challenges, or insufficient market penetration. Additionally, the reliance on early adoption by healthcare providers and insurers may not sustain long-term growth if broader acceptance is not achieved.
Insurance Coverage and Reimbursement: Although Express Scripts has added CARDAMYST to its formulary, coverage is currently limited to 25% of commercially insured lives. Delays or failures in securing additional payer agreements could hinder patient access and limit revenue growth.
Phase III Clinical Trial for AFib-RVR: The success of the ReVeRa-301 Phase III trial is critical for future growth. Any delays in patient recruitment, trial execution, or unfavorable results could significantly impact the company's strategic objectives and financial performance.
Financial Sustainability: Despite a strong cash position, the company reported a net loss of $26.1 million in Q1 2026. High operating expenses, particularly related to the commercial launch and clinical trials, could strain financial resources if revenue growth does not accelerate.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Phase III trial for atrial fibrillation with rapid ventricular rate (AFib-RVR): The company has initiated the Phase III trial named ReVeRa-301 for AFib-RVR. The trial is based on the successful Phase II study, which showed statistically significant and clinically meaningful results. The trial will use the same 70-milligram dose and repeat dose regimen as the approved CARDAMYST for SVT. Enrollment of the first patient is expected in the second half of 2026, with updates to follow as the study progresses.
Financial runway and resource management: The company has a strong balance sheet with approximately $184 million in cash, cash equivalents, and short-term investments as of March 31, 2026. This is expected to support operations, including the CARDAMYST launch and the ReVeRa-301 study, into the second half of 2027.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the mix of prescribers at this point and how you expect that evolution of the mix to reflect downstream on the percentage of patients?
A:The majority of early prescriptions are from clinical cardiologists (50%), followed by electrophysiologists (25%), and the remaining 25% from nurse practitioners, physician assistants, and a few primary care physicians. Over time, the percentage of prescriptions from clinical and interventional cardiologists is expected to increase, while electrophysiologists will continue to prescribe but at a reduced rate. Nurse practitioners and physician assistants are expected to play a larger role as practices become more comfortable prescribing the drug.
Q:How much free drug has been given away, and will bridging programs continue to be part of the 2026 effort?
A:The company has not given away a significant amount of free drug. The goal is to ensure that payers are aware of demand by going through prior authorization or medical exception processes before providing assistance. Bridging programs are being used to convert patients who do not pass medical exceptions, and this approach will continue.
Q:Can you provide details on the ReVeRa-301 study, including patient enrollment and timeline expectations?
A:The ReVeRa-301 study targets patients with atrial fibrillation and rapid ventricular rate (AFib-RVR). The study aims to enroll 150-200 total events over approximately two years. It will involve multi-country, multi-site participation with up to 600 patients enrolled to achieve the target events. The study is powered at 90% to deliver results based on symptomatic improvement.
Q:What kind of prior authorization is required for Express Scripts formulary decision, and why does the gross-to-net seem high?
A:Express Scripts coverage reduces the paperwork burden for physicians, making it easier to prescribe and refill the drug. The gross-to-net appears high because the company is ensuring payers see demand by not providing free drugs initially. The reported $800 per script calculation was incorrect; the actual figure is lower due to the first quarter of launch and the use of denial conversion programs.
Q:Can the Express Scripts agreement accelerate prescription volume, and what are the key levers for increasing physician prescribing and patient utilization?
A:Yes, the Express Scripts agreement can accelerate prescription volume by reducing paperwork and improving coverage. Key levers for increasing prescribing include promotional efforts, physician awareness, and trialing the drug. For patient utilization, successful experiences with the drug and the ability to refill prescriptions will drive repeat usage.
Q:How is the launch tracking compared to expectations, and what is the strategy for targeted DTC spend?
A:The launch is tracking well, with positive feedback from physicians and early patient experiences. Express Scripts coverage is ahead of expectations. Targeted DTC spend is being piloted to ensure effective use of resources, with broader efforts planned once physician awareness and trialing are sufficient.
Q:How many touchpoints are required for physicians to prescribe, and are there differences between electrophysiologists and cardiologists?
A:Many physicians prescribe after one or two interactions, but more touchpoints are needed for broader adoption. Electrophysiologists and cardiologists have different use cases for the drug, with electrophysiologists focusing on bridging patients to ablation and cardiologists managing newly diagnosed or dissatisfied patients.
Q:When will the sales force reach maximum productivity, and are there plans for expansion?
A:Sales force productivity is expected to improve in the second half of the year as they reach more physicians and increase frequency. Expansion will be considered based on ROI and coverage progress, with a focus on balancing sales force efforts and patient activation strategies.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact amount of free drug given away and the precise timeline for achieving broader payer coverage beyond Express Scripts.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AFib RVR
AFib study
CARDAMYST formulary
CARDAMYST pharmacy
CEO President
Executive Director
III AFib
III trial
PBMs
Phase III
President Executive
ReVeRa study
SVT
benefit manager
channel
conduct
coverage decision
decrease
dose
drug health
event story
fibrillation rate
frequency
pharmacy benefit
physician nurse
placebo
prescription health
rate AFib
research
safety profile
script month
self administration
site
trial patient
win
MIST Transcript
Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call reveals several concerns: low revenue, increased commercial expenses, and a significant net loss. Despite positive elements like reduced R&D and G&A expenses, and an Express Scripts agreement, the Q&A highlights uncertainties, especially regarding prescription volume and payer coverage. The lack of clear guidance on free drug distribution and payer expansion further clouds the outlook. Overall, the financial strain and ambiguous responses suggest a negative sentiment, likely impacting the stock price negatively in the short term.
Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript
Unknown3-20
The earnings call presents a mixed picture. Financial performance shows increased expenses and net loss, raising concerns. However, the company has a strong cash position and positive milestone revenue. The Q&A reveals challenges in insurance coverage and reimbursement delays, but also highlights broad prescriber feedback and patient support systems. The lack of specific data on patient outcomes and reimbursement timelines adds uncertainty. While there are positive aspects, such as milestone revenue, the overall sentiment is tempered by the challenges and uncertainties, leading to a neutral stock price prediction.
MIST Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
